William Elias Shomali, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shomali’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A140677 · Current
Licensed to practise in California · since 2016 · expires 2028-01-31 · University of Jordan Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$87,388
Medicare paid this office $87,388 for 241 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $22,808 | $105 |
| Long return visit (40+ min) | 65 | $19,268 | $162 |
| Return visit (30+ min) | 56 | $9,987 | $117 |
| Long return visit (40+ min) | 44 | $9,911 | $127 |
| New patient visit (60+ min) | 40 | $5,880 | $147 |
See all 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $22,808 | $105 |
| Long return visit (40+ min) | 65 | $19,268 | $162 |
| Return visit (30+ min) | 56 | $9,987 | $117 |
| Long return visit (40+ min) | 44 | $9,911 | $127 |
| New patient visit (60+ min) | 40 | $5,880 | $147 |
| New patient visit (60+ min) | 21 | $4,221 | $201 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,409 | $148 |
| Hospital discharge day management, more than 30 minutes | 30 | $3,217 | $104 |
| Return visit (30+ min) | 29 | $3,206 | $82 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 52 | $1,034 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 35 | $659 | $15 |
Who their Medicare patients are
241 Original Medicare patients in 2024. Average age 75 · Women 52% · Also on Medicaid 21% · Health risk score 2.36. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 75% · Coronary heart disease 39% · Chronic kidney disease 34% · Diabetes 27% · Heart failure 26% · Cancer 23% · Atrial fibrillation 23% · Depression 23% · COPD 19% · Dementia 13% · Stroke 13%.
The office billed $388,869, Medicare allowed $113,752 and paid $87,388; for 812 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 241 | 812 | 75 | 2.36 | $388,869 | $87,388 |
| 2023 | 235 | 690 | 74 | 2.06 | $304,176 | $74,448 |
| 2022 | 210 | 736 | 73 | 2.48 | $333,814 | $73,364 |
| 2021 | 169 | 503 | 72 | 2.25 | $241,189 | $53,359 |
| 2020 | 71 | 235 | 72 | 2.61 | $106,602 | $24,460 |
| 2016 | 35 | 109 | 70 | 3.22 | $39,283 | $6,511 |
| 2015 | 31 | 77 | 64 | 1.90 | $23,714 | $4,579 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $28,383 | $108 |
| Long return visit (40+ min) | 60 | $15,287 | $128 |
| Return visit (30+ min) | 77 | $10,036 | $74 |
| New patient visit (60+ min) | 51 | $7,758 | $152 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,237 | $160 |
| Hospital discharge day management, more than 30 minutes | 26 | $2,892 | $107 |
| Short return visit (20+ min) | 19 | $1,220 | $58 |
2022: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $30,843 | $93 |
| Return visit (30+ min) | 82 | $14,866 | $80 |
| New patient visit (60+ min) | 54 | $8,228 | $152 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $8,195 | $182 |
| Long return visit (40+ min) | 30 | $5,541 | $132 |
| Hospital discharge day management, more than 30 minutes | 19 | $2,189 | $100 |
2021: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $21,348 | $94 |
| New patient visit (60+ min) | 57 | $9,082 | $159 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $7,324 | $183 |
| Return visit (30+ min) | 42 | $6,651 | $88 |
| Long return visit (40+ min) | 20 | $2,876 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,445 | $66 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,287 | $99 |
2020: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $12,243 | $96 |
| New patient visit (60+ min) | 24 | $3,576 | $149 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $3,407 | $189 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,208 | $101 |
| Return visit (30+ min) | 11 | $1,094 | $73 |
2016: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $3,801 | $55 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,192 | $99 |
2015: 1 service
| Short return visit (20+ min) | 12 | $472 | $39 |
Medicaid work
$3,051 in 2024
Medicaid paid $3,051 for 53 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 53 | $3,051 |
| 2024 | 53 | 1 | 12 | $3,051 |
| 2023 | 27 | 1 | 14 | $1,301 |
| 2021 | 53 | 1 | 12 | $3,205 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 27 | $1,301 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 53 | $3,205 |
Drugs they prescribed that Part D paid
$208,919
Pharmacies billed $208,919 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 95) in 2024. At or below the middle of the specialty; the typical medical oncology clinician is at 6%.
76 generic and 19 brand-name prescriptions · $208,919 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Hydroxyurea | 25 | $238 | $10 |
| Acyclovir | 14 | $164 | $12 |
Year by year
| 2024 | 95 | 39 | 0% (0) | 20% | $208,919 |
| 2023 | 100 | 37 | 0% (0) | None | $215,544 |
| 2022 | 57 | 31 | 0% (0) | None | $61,442 |
| 2021 | 54 | 25 | None | None | $60,881 |
| 2020 | 70 | 28 | 0% (0) | 24% | $219,706 |
| 2019 | 33 | 16 | 0% (0) | None | $101,486 |
| 2016 | 22 | None | 0% (0) | None | $356 |
| 2015 | 325 | 42 | None | None | $17,835 |
| 2014 | 195 | 43 | None | 15% | $11,010 |
| 2013 | 177 | 50 | None | None | $8,190 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2021: 1 drug
| Hydroxyurea | 11 | $159 | $14 |
2020: 1 drug
| Hydroxyurea | 11 | $549 | $50 |
2015: 6 drugs
| Atorvastatin | 11 | $309 | $28 |
| Metoprolol | 38 | $194 | $5 |
| Amlodipine Besylate | 29 | $147 | $5 |
| Hydrochlorothiazide | 24 | $106 | $4 |
| Lisinopril | 19 | $70 | $4 |
| Cyclobenzaprine | 11 | $35 | $3 |
2014: 4 drugs
| Atorvastatin | 14 | $375 | $27 |
| Carvedilol | 11 | $103 | $9 |
| Lisinopril | 16 | $102 | $6 |
| Amlodipine Besylate | 14 | $54 | $4 |
2013: 1 drug
| Amlodipine Besylate | 11 | $113 | $10 |
Money from drug and device companies
$1,962 in 2025
| 2025 | 2 | 2 | $1,940 | $1,962 |
| 2024 | 1 | 1 | $8,972 | $8,972 |
| 2022 | 1 | 1 | $2,896 | $2,896 |
| 2021 | 2 | 3 | $12,546 | $12,546 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 2 published payments
| Incyte | Consulting · 2025-12-18 | None | $1,940 |
| Celgene | Meals · 2025-10-02 | Reblozyl | $22 |
See earlier years (2024, 2022, 2021)
2024: $8,972
| Incyte | None | $8,972 | 1 payment
|
2022: $2,896
| Incyte | None | $2,896 | 1 payment
|
2021: $12,546
| Incyte | None | $9,700 | 2 payments
|
| Blueprint Medicines | None | $2,846 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Incyte Corporation · A Phase 1, Open-Label, Multicenter Study of Inca033989 in Participants With Myeloproliferative Neoplasms · 2025 | Their institution | $640,044 |
| Incyte Corporation · A Phase 1/2, Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy in Participants With Anemia Due To Myelodysplastic Syndromes Or Multiple Myeloma · 2024 | Their institution | $214,941 |
| Incyte Corporation · A Phase 1, Open-Label, Multicenter Study of Inca033989 in Participants With Myeloproliferative Neoplasms · 2024 | Their institution | $198,066 |
| Blueprint Medicines Corporation · A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of Blu-263 in Indolent Systemic Mastocytosis · 2023 | Their institution | $159,714 |
| Incyte Corporation · A Phase 1/2, Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy in Participants With Anemia Due To Myelodysplastic Syndromes Or Multiple Myeloma · 2023 | Their institution | $151,364 |
| Blueprint Medicines Corporation · A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of Blu-263 in Indolent Systemic Mastocytosis · 2022 | Their institution | $120,408 |
| Blueprint Medicines Corporation · A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of Blu-263 in Indolent Systemic Mastocytosis · 2024 | Their institution | $92,841 |
| Incyte Corporation · Ruxolitinib in Primary Eosinophilic Disorders and Idiopathic Hypereosinophilic Syndrome · 2021 | Their institution | $76,250 |
| Incyte Corporation · A Phase 1/2, Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy in Participants With Anemia Due To Myelodysplastic Syndromes Or Multiple Myeloma · 2025 | Their institution | $60,284 |
| Incyte Corporation · Ruxolitinib in Primary Eosinophilic Disorders and Idiopathic Hypereosinophilic Syndrome · 2023 | Their institution | $59,580 |
| Incyte Corporation · Ruxolitinib in Primary Eosinophilic Disorders and Idiopathic Hypereosinophilic Syndrome · 2024 | Their institution | $37,750 |
| SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of Blu-263 in Indolent Systemic Mastocytosis · 2025 | Their institution | $31,214 |
| Incyte Corporation · This Phase 1/2, Open-Label, Dose-Finding Study Is Intended To Evaluate the Safety and Tolerability, Pk, Pd, and Efficacy of Incb000928 Administered As Monotherapy in Participants With Mds Or Mm Who Are Transfusion-Dependent Or Present With Symptomatic Anemia. · 2025 | Their institution | $29,513 |
| Incyte Corporation · A Phase 1/2, Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy in Participants With Anemia Due To Myelodysplastic Syndromes Or Multiple Myeloma · 2021 | Their institution | $29,421 |
| Blueprint Medicines Corporation · A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of Blu-263 in Indolent Systemic Mastocytosis · 2025 | Their institution | $28,643 |
| Incyte Corporation · Ruxolitinib in Primary Eosinophilic Disorders and Idiopathic Hypereosinophilic Syndrome · 2025 | Their institution | $16,367 |
| Incyte Corporation · Ruxolitinib in Primary Eosinophilic Disorders and Idiopathic Hypereosinophilic Syndrome · 2022 | Their institution | $6,620 |
| Incyte Corporation · A Phase 1/2, Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy in Participants With Anemia Due To Myelodysplastic Syndromes Or Multiple Myeloma · 2022 | Their institution | $5,098 |
| Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2022 | Their institution | $2,639 |
| Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2021 | Their institution | $1,601 |
| Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2023 | Their institution | $823 |
| Incyte Corporation · A Phase 1, Open-Label, Multicenter Study of Inca033989 in Participants With Myeloproliferative Neoplasms · 2023 | Their institution | $107 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1407113871
- Licence
- CA A140677, OH 35.125660California A140677: Current · expires 2028-01-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X); Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2012-04-23
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.